A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
Atavistik Bio, Inc
Duke University
AstraZeneca
NeoTX Therapeutics Ltd.
Vanderbilt-Ingram Cancer Center
Exelixis
Cancer Research UK
University of Alabama at Birmingham
Klus Pharma Inc.
Tempus AI
Theratechnologies
Xencor, Inc.
Agenus Inc.
Checkpoint Therapeutics, Inc.
Carisma Therapeutics Inc